Stockscreener 앱 받기
528.79
0.76%
-4.07
시간 외 거래:
528.79
전일 마감가:
$532.86
열려 있는:
$534.72
하루 거래량:
659.26K
Relative Volume:
1.21
시가총액:
$41.71B
수익:
$4.45B
순이익/손실:
$1.10B
주가수익비율:
38.91
EPS:
13.591
순현금흐름:
$1.06B
1주 성능:
-5.59%
1개월 성능:
-8.95%
6개월 성능:
-23.36%
1년 성능:
+3.28%
1일 변동 폭
$527.12
$540.95
1주일 범위
$523.38
$559.90
52주 변동 폭
$496.61
$769.98
아이덱스 래버러토리스 Stock (IDXX) Company Profile
명칭
Idexx Laboratories Inc
전화
(207) 556-0300
주소
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, WAT, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
아이덱스 래버러토리스 Stock (IDXX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | Citigroup | Neutral |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-31 | 업그레이드 | Stifel | Hold → Buy |
| 2025-10-01 | 개시 | UBS | Neutral |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-01 | 개시 | Jefferies | Buy |
| 2024-12-02 | 개시 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | BTIG Research | Buy |
| 2024-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | 개시 | Exane BNP Paribas | Outperform |
| 2023-12-04 | 업그레이드 | Cleveland Research | Neutral → Buy |
| 2023-08-02 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-07-12 | 개시 | Piper Sandler | Overweight |
| 2022-05-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-08 | 개시 | Atlantic Equities | Overweight |
| 2021-11-18 | 개시 | Morgan Stanley | Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-07-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-17 | 개시 | Barclays | Overweight |
| 2019-09-09 | 개시 | Goldman | Neutral |
| 2019-05-23 | 개시 | Guggenheim | Buy |
| 2018-11-02 | 재확인 | BofA/Merrill | Buy |
| 2018-05-07 | 재확인 | Stifel | Buy |
| 2018-01-16 | 개시 | Piper Jaffray | Overweight |
| 2017-08-23 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | 업그레이드 | CL King | Neutral → Buy |
| 2017-02-03 | 다운그레이드 | Feltl & Co. | Hold → Sell |
| 2016-09-29 | 재개 | BofA/Merrill | Neutral |
| 2016-08-16 | 재확인 | Stifel | Buy |
| 2016-08-03 | 업그레이드 | Northcoast | Sell → Neutral |
| 2016-07-20 | 재확인 | Canaccord Genuity | Buy |
| 2016-04-19 | 재확인 | Canaccord Genuity | Buy |
| 2016-04-01 | 개시 | CL King | Neutral |
| 2016-03-21 | 재확인 | Stifel | Buy |
| 2016-02-04 | 개시 | Credit Suisse | Outperform |
| 2015-10-29 | 재확인 | Stifel | Buy |
| 2015-08-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | 재확인 | Stifel | Buy |
| 2015-07-23 | 재확인 | Canaccord Genuity | Buy |
모두보기
아이덱스 래버러토리스 주식(IDXX)의 최신 뉴스
IDEXX Laboratories stock (US45167R1041): Diagnostics demand keeps investors focused - AD HOC NEWS
IDXX Technical Analysis & Stock Price Forecast - Intellectia AI
Northwestern Mutual Wealth Management Co. Increases Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Idexx Laboratories Shareholders Approve Governance and Meeting Reforms - TipRanks
IDEXX Laboratories stock (US45168D1046): Q1 2025 earnings highlight growth in pet diagnostics - AD HOC NEWS
IDEXX (NASDAQ: IDXX) declassifies board, grants 25% special-meeting right - Stock Titan
Capitalizing On Growth Prospects, Irene Chang Britt Acquires IDEXX Laboratories Stock Options Worth $771 - Benzinga
Bruce L Claflin Backs Up Beliefs With A Notable Acquisition Of IDEXX Laboratories Stock Options Worth $77 - Benzinga
In A Strategic Move, Joseph L Hooley Acquires IDEXX Laboratories Stock Options Worth $771: Enhancing Valu - Benzinga
Karen Peacock At IDEXX Laboratories Exercises Options Worth $0 - Benzinga
Engaging In Insider Activity, Sam Samad At IDEXX Laboratories Exercises Options Worth $0 - Benzinga
IDEXX announces UK availability of cancer Dx panel for early detection of canine lymphoma - MSN
IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day - 01net
IDEXX (IDXX) director Vandebroek receives RSU and option grants as compensation - Stock Titan
Director Sam Samad (NASDAQ: IDXX) receives new stock units and options grant - Stock Titan
IDEXX (IDXX) director granted stock options and deferred stock units - Stock Titan
IDEXX (IDXX) director Lawrence Kingsley awarded RSUs and stock options - Stock Titan
IDEXX (IDXX) grants director RSUs and stock options at $533.92 - Stock Titan
IDEXX (NASDAQ: IDXX) director Hooley granted deferred units and options - Stock Titan
IDEXX (IDXX) director Stuart Essig granted RSUs and options in new equity awards - Stock Titan
IDEXX (NASDAQ: IDXX) director Bruce Claflin granted deferred stock units and options - Stock Titan
IDEXX (IDXX) director receives new stock options and deferred units - Stock Titan
Do You Believe in the Long-Term Growth Potential of IDEXX Laboratories (IDXX)? - Insider Monkey
IDEXX Laboratories stock (US45167R1041): Q1 earnings beat with 14.3% revenue growth - AD HOC NEWS
IDEXX Laboratories, Inc. Stock 12‑Month Price Target Cut to $714.36, Implies 35% Upside - TradingView
HARVEY INVESTMENT CO LLC's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
TCW Concentrated Large Cap Growth Fund's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
IDXX Technical Analysis | Trend, Signals & Chart Patterns | IDEXX LABORATORIES INC (NASDAQ:IDXX) - ChartMill
IDEXX Laboratories, Inc. Stock 12‑Month Price Target Cut to $721.5, Implies 35% Upside - TradingView
IDEXX Laboratories Inc (IDXX) Stock Down 4.7% -- Now Undervalued? GF Score: 98/100 - GuruFocus
IDEXX Laboratories stock (US45167R1041): Shares fall 5% despite beating earnings estimates - AD HOC NEWS
IDEXX Laboratories Inc (IDXX) Shares Fall 5.0% -- What GF Score of 99 Tells Investors - GuruFocus
IDEXX (IDXX) director’s RSUs vest into 257 shares, holdings updated - Stock Titan
IDEXX (IDXX) director Szostak adds 257 shares as RSUs vest into stock - Stock Titan
IDEXX (IDXX) director Karen Peacock converts 101 RSUs into 102-share holding - Stock Titan
Director at IDEXX Laboratories (IDXX) gains 339 shares from RSU vesting - Stock Titan
IDEXX Laboratories (NASDAQ: IDXX) director gains 257 shares from RSU vesting - Stock Titan
Director Hooley of IDEXX (NASDAQ: IDXX) gains 158 common shares via RSU vesting - Stock Titan
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch
BofA Sees Slower InVue Installations as Headwind for IDEXX Laboratories, Inc. (IDXX) - Insider Monkey
IDEXX Laboratories Drops 5.8% Amid Sector-Wide Selling - AlphaStreet
What you need to know ahead of IDEXX Laboratories' earnings release - MSN
IDEXX Laboratories stock (US45168D1046): Mixed price moves amid strong earnings and valuation debate - AD HOC NEWS
IDEXX Laboratories Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here’s Why IDEXX Laboratories Stock Could Deliver Around 11% Annual Returns Despite a 15% YTD Pullback - TIKR.com
Truist Financial Corp Sells 1,993 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Analyst Estimates: Here's What Brokers Think Of IDEXX Laboratories, Inc. (NASDAQ:IDXX) After Its First-Quarter Report - Yahoo Finance
Companion Animal Diagnostics Market Valued at USD 7.6 Billion - openPR.com
Jefferies Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Cuts Target Price to $729 - Moomoo
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
아이덱스 래버러토리스 (IDXX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아이덱스 래버러토리스 주식 (IDXX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SZOSTAK M ANNE | Director |
May 07 '26 |
Option Exercise |
0.00 |
257 |
0 |
519 |
| Peacock Karen | Director |
May 07 '26 |
Option Exercise |
0.00 |
101 |
0 |
102 |
| Kingsley Lawrence D | Director |
May 07 '26 |
Option Exercise |
0.00 |
339 |
0 |
9,568 |
| JUNIUS DANIEL M | Director |
May 07 '26 |
Option Exercise |
0.00 |
257 |
0 |
3,561 |
| HOOLEY JOSEPH L | Director |
May 07 '26 |
Option Exercise |
0.00 |
158 |
0 |
276 |
| Underberg Sharon E. | EVP, GC & Corporate Secretary |
Mar 03 '26 |
Option Exercise |
505.53 |
197 |
99,589 |
7,138 |
| Hunt Nimrata | Executive Vice President |
Mar 03 '26 |
Sale |
634.57 |
1,758 |
1,115,577 |
18,141 |
1.20%
자본화:
|
볼륨(24시간):